RTW Investments LP Decreases Stock Holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

RTW Investments LP decreased its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 23.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,506,102 shares of the company’s stock after selling 750,000 shares during the period. RTW Investments LP’s holdings in Milestone Pharmaceuticals were worth $5,914,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares in the last quarter. National Bank of Canada FI raised its stake in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after acquiring an additional 11,600 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at $73,000. XTX Topco Ltd purchased a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at $80,000. Finally, Northern Trust Corp raised its stake in shares of Milestone Pharmaceuticals by 112.6% in the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after acquiring an additional 30,772 shares during the period. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Trading Down 1.7%

NASDAQ MIST opened at $1.15 on Friday. The company’s 50-day moving average price is $1.28 and its 200-day moving average price is $1.71. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The stock has a market cap of $61.48 million, a PE ratio of -1.42 and a beta of 0.86. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.12). Equities research analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on MIST shares. Cowen downgraded shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. TD Cowen downgraded shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Finally, TD Securities downgraded shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $17.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.